Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 1 [0.03%]
靶向放射性药物治疗：进展、投资动态及未来方向（一）
Catello Somma,Richard Zimmermann,Germo Gericke et al.
Catello Somma et al.
Radiopharmaceuticals have emerged as a transformative modality in precision oncology, with growing potential in non-oncologic indications, such as severe autoimmune diseases and rheumatology, because of their capacity for targeted therapeut...
Radiopharmaceutical Therapy Meets Radiobiology: Implications for Trial Design and DNA Repair Inhibitor Combinations [0.03%]
放射性药物治疗与放疗生物学的结合：对临床试验设计和DNA修复抑制剂组合的意义
Katharina Lückerath,Pablo Mínguez Gabiña,Uta Eberlein et al.
Katharina Lückerath et al.
Radiopharmaceutical therapy (RPT) delivers protracted, low absorbed dose rate radiation over time, with cellular DNA repair capacity potentially limiting its efficacy. This article explores how lessons from radiobiology-particularly regardi...
Nephron-Level Dosimetry Reveals Increased Absorbed Dose Heterogeneity of 161Tb- Versus 177Lu-DOTATATE in Murine Kidneys Despite Similar Pharmacokinetics [0.03%]
基于小鼠肾脏的单个肾单位剂量学研究发现，尽管药代动力学相似，但161Tb-DOTATATE的吸收剂量异质性高于177Lu-DOTATATE
Michelle Andersson,Tomas Opsomer,Clarita Saldarriaga Vargas
Michelle Andersson
The β--emitter 161Tb is emerging as a promising radionuclide for radiopharmaceutical therapy because of its increased yield of low-energy electrons compared with 177Lu. This results in an increased localized absorbed dose, potentially infl...
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 2 [0.03%]
靶向放射性药物治疗：进展、投资动态和未来方向（第二部分）
Catello Somma,Richard Zimmermann,Germo Gericke et al.
Catello Somma et al.
Radiopharmaceutical therapy is rapidly expanding, propelled by scientific and investment momentum. This paper analyzes the evolving dynamics of clinical innovation, infrastructure build-out, and financial investment that are shaping the com...
Reply: A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT [0.03%]
回应：在常规实施术后SPECT之前要求提供高水平证据的呼吁
Carlos Uribe,Amir Iravani,Bital Savir-Baruch et al.
Carlos Uribe et al.
Management of Hemodialyzed Patients Treated with Radioactive Iodine for Thyroid Cancer: How Could We Improve It? Tracks from the Lille Experience [0.03%]
经放射性碘治疗甲状腺癌的血液透析患者管理：我们如何才能改善它？里尔经验的启示
Benjamin Chevalier,Laura Devos,Clio Baillet et al.
Benjamin Chevalier et al.
The use of radioactive iodine (RAI) for patients with thyroid cancer (TC) who are also treated with hemodialysis for end-stage renal disease (HD-ESRD) remains challenging, with several issues still unresolved. We report our tertiary referra...
Immuno-PET/CT Imaging of Trop2 Expression with [18F]AlF-RESCA-RT4 Enhances Diagnosis of Breast Cancers and the Metastases [0.03%]
用于Trop2表达的[18F]AlF-RESCA-RT4免疫PET/CT成像提高乳腺癌及其转移灶的诊断能力
Wenzhi Jia,Tingting Yan,Shuxian An et al.
Wenzhi Jia et al.
This study aimed to evaluate human trophoblast cell surface antigen 2 (Trop2) expression across molecular subtypes of breast cancer and assess the diagnostic performance of a novel Trop2-targeted tracer, [18F]AlF-RESCA-RT4, compared with 18...
Diagnostic Performance of FAPI PET in Patients with Breast Cancer: A Systematic Review [0.03%]
FAPIPET在乳腺癌患者中的诊断性能系统评价
Lisa E H W Duijx,Melissa Lenaerts,Marjolein L Smidt et al.
Lisa E H W Duijx et al.
We evaluated the diagnostic performance of fibroblast activation protein inhibitor (FAPI) PET for lesion detection at breast cancer diagnosis and response assessment after neoadjuvant chemoimmunotherapy (NAC) and compared these findings wit...
Widespread Prostate Cancer Osseous Metastases: Negative on 18F-Piflufolastat PET but Positive on 18F-Fluciclovine PET [0.03%]
广泛转移的前列腺癌骨转移：18F-Piflufolastat PET阴性但18F-Fluciclovine PET阳性
Gary A Ulaner,Richard Lam
Gary A Ulaner
[68Ga]Ga-DOTA-5G PET/CT Detects Brain and Bone Metastases in a Patient with Metastatic Pancreatic Cancer [0.03%]
[68Ga]Ga-DOTA-5G PET/CT在转移性胰腺癌患者中检测到脑和骨转移灶
Cameron C Foster,Tanushree Ganguly,Sven H Hausner et al.
Cameron C Foster et al.